Prosecution Insights
Last updated: May 29, 2026

Vivex Biologics Group Inc.

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (40%)
1
Easy (20%)
2
Unknown (40%)

Rejection Statute Mix

BucketCases
§103 only2 (40%)
§112 only1 (20%)
No statute on record2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
20% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
D' AMBROSIO, THEA 1 55.6% +56.8%
KIM, TAEYOON 1 51.5% +51.4%
PASQUALINI, HANNA LOUISE 1 40.0% +33.3%
MCCARTY, PATRICK M 1 60.6% +24.0%
PYLA, EVELYN Y 1 55.1% +47.8%

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18051663 EXOSOME COMPOSITION AND METHOD OF MANUFACTURE KIM, TAEYOON 81d overdue
15898558 COATED BIOLOGICAL COMPOSITION PYLA, EVELYN Y 79d overdue
17895276 UMBILICAL CORD BIOLOGIC STENT OR CONDUIT PASQUALINI, HANNA LOUISE 17d overdue
17714378 MIXING CONTAINER AND METHOD OF USE MCCARTY, PATRICK M 11d overdue
18058112 SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE D' AMBROSIO, THEA 10d overdue

Top Art Units

Art UnitApps
1654 1
1631 1
3774 1
1774 1
1633 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18058112 SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE D' AMBROSIO, THEA 1654 §103 Non-Final OA 10d overdue Pending Nov 22, 2022
18051663 EXOSOME COMPOSITION AND METHOD OF MANUFACTURE KIM, TAEYOON 1631 Other Final Rejection 81d overdue Pending Nov 01, 2022
17895276 UMBILICAL CORD BIOLOGIC STENT OR CONDUIT PASQUALINI, HANNA LOUISE 3774 §103 Final Rejection 17d overdue Pending Aug 25, 2022
17714378 MIXING CONTAINER AND METHOD OF USE MCCARTY, PATRICK M 1774 Other Non-Final OA 11d overdue Pending Apr 06, 2022
15898558 COATED BIOLOGICAL COMPOSITION PYLA, EVELYN Y 1633 §112 Non-Final OA 79d overdue Pending Feb 17, 2018

Managing Vivex Biologics Group Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month